Naturopathic Anti-Tumoral Treatment & 8 Year Survival Benefit Statistics: A Single-Centre Experience

Gurdev Parmar
Integrated Health Clinic
Fort Langley BC Canada

Presented at 36th ICHS, Budapest, 2018

Cite this article as:
Parmar G. (2018): Naturopathic Anti-Tumoral Treatment & 8 Year Survival Benefit Statistics: A Single-Centre Experience; Oncothermia Journal 24:405-425
www.oncothermia-journal.com/journal/2018/Naturopathic_anti_tumoral_teatment.pdf

Naturopathic Anti-Tumoral Treatment & 8 Year Survival Benefit Statistics: A Single-Centre Experience"

Gurdev Parmar
Integrated Health Clinic, Cancer Care Center, Fort Langley, B.C. Canada

Background
There is a considerable amount of research supporting the use of hyperthermia as an adjuvant treatment in oncology. Both modulated electrohyperthermia (mEHT) and fever-range whole body hyperthermia (FR-WBHT) have been added to our adjuvant treatment of various cancer types. This study will present the findings of these treatments over the past 8 years in our integrative naturopathic oncology setting. There will also be a presentation of several exceptional case studies from this dataset, which will help illustrate the process by which these treatments are incorporated into an integrative treatment approach.

Methods
mEHT was administered using the Oncotherm EHY-2000+, and FR-WBHT using the Heckel HT-2000.

Results
An examination of the data from the past 8 years will be provided. mEHT has been administered to hundreds of patients with over 35 cancer types. Data elements include patient statistics, cancer group & type, treatment(s) used, adverse events, overall survival (OS), diagnostic imaging & blood test results. We have also now provided FR-WBHT to hundreds of patients and we have collected similar data in the evaluation of this treatment's benefit. An initial analysis of this data will be provided. A Best Case Series of several exceptional case reports will also be presented.

Conclusion
mEHT and FR-WBHT are safe treatments with very few adverse events or side effects, allowing patients to maintain a high quality of life. Moreover, our initial data indicates that the addition of these therapies into an integrative oncology setting provides benefits to PFS and OS, as well as to QOL.


Integrated Health Clinic
Cancer Care Center
BRINGING HOPE TO CANCER CARE
Naturopathic Anti-Tumoral Treatment & 8 Year Survival Benefit Statistics:
A Single-Centre Experience
Fort Langley BC Canada
Nutritional Counselling
Education on the influence of diet & exercise
Intravenous Therapies
Medicine, nutrients & minerals delivered directly to the patient
Hyperthermia
Heat & EMF induced response
Laboratory Testing
Understanding the patient's specific condition
Targeted Supplementation
Assessing each patient's specific requirements
Injection Therapies
Focused immune support and energy management
INTEGRATIVE THERAPIES
Exceptional Technology...The Right People...Uncompromising Care
IHC Cancer Care | 2018
www.integratedhealthclinic.com

IHC Cancer Care
OUR MODEL
Integrative Cancer Care
Integrative Cancer Care
Treating the Whole Patient
Primary Cancer Therapies
Cytotoxic treatments that also work with standard treatments improving efficacy & reduce SE's
Immune System Therapies
Therapies that improve immune management of cancer
Supportive Protocols
Managing the unique issues faced by each patient maximizing quality of life throughout their care
Prevention & Survivorship
Personalizing cutting edge survivorship, surveillance and prevention strategies
IHC Cancer Care | 2018
www.integratedhealthclinic.com

Primary Cancer Therapies

Killing Cancer Cells

Loco-Regional Hyperthermia

Using heat and EMF to kill cancer cells & enhance CT/RT

I.V. Therapy

Direct infusion of high dose vitamins & other medicines

Injection Therapy

Direct introduction of focused cancer fighting agents

Targeted Supplementation

Addressing known molecular targets of each patient's cancer

Prescriptive Medications

Repurposed drugs used to manage known targets of cancers

Conventional Therapy Sensitization

Maximizing conventional treatment efficacy

Sonodynamic Therapy

Ultrasound induced activation of cancer fighting agents

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Immune System Therapies

Boosting Natural Systems

I.V. Therapy

Infusions of immunologic medicines such as Vitamin C

Injection Therapy

Focused immune support such as mistletoe therapy

Targeted Supplementation

Oral meds to support the branches of the immune system

Biological Therapy

Biological agents to stimulate immune activity

Immunotherapy Sensitization

Supporting PD-1/PD-L1, CTL-4 and other approaches

Body Warming Therapy

Fever response activation

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Supportive Protocols

Achieving Wellness

Detoxification / Chelation
Removes toxins, heavy metals and other waste materials

Vital Organ Support
Targeted support for the liver, kidneys, skin and bowels/biome

Laboratory Testing
Use laboratories worldwide to provide best practices

Dietary Counselling
Understanding the best foods for your specific body/disease

Lifestyle Counselling
Harnessing the benefits of exercise, stress management, mindfulness, etc.

Acupuncture & TCM
Using acupuncture & herbs to support healthy Qi

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Prevention & Survivorship

Life Without Cancer

I.V. Therapy
Infusions to optimize nutrition and tissue health

Injection Therapy
To support a healthy immune system

Targeted Supplementation
Addressing each patients specific need for support.

Dietary Counselling
Eating foods with known anti-cancer benefits

Lifestyle Counselling
Harnessing the benefits of exercise, stress management, mindfulness and other cancer prevention strategies

Detoxification / Chelation
Remove toxins, heavy metals and other waste materials known to interfere with proper body function

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Dr. Gurdev Parmar, BSc, ND, FABNO
Integrated Health Clinic
Fort Langley BC Canada

Naturopathic Anti-Tumoral Treatment & 8 Year Survival Benefit Statistics: A Single-Centre Experience

Disclosure

Owner Integrated Health Clinic, which offers Hyperthermia Treatment

Ownership interests in Teneovita Medical Innovations, Inc., an international distributor of hyperthermia devices



Research & Ethics

The CCNM Research and ethics board (REB) has provided review and oversight for this research project, in order to assure that it meets all scientific and ethical principles, and that it complies with all applicable regulations and standards pertaining to human participant protection.




Background
The benefit of hyperthermia as an integrated cancer therapy is well established in many parts of the world [1,2,3,4]
The application of heat (locally or as a whole body treatment) is not widely administered in North America, partly due to limited available research in this geographic location.
The compelling evidence supporting its safety and use as an adjunct to standard of care in Europe and Asia highlights the need for further hyperthermia research in North America [5,6]
IHC Cancer Care | 2018
www.integratedhealthclinic.com


Background
In June 2010 Integrated Health Clinic successfully applied for a Special Access License & then a Class 3 Medical Device License to import and use an Oncotherm modulated electro-hyperthermia device, a first in Canada & the USA.
As a naturopathic oncologist, I have a 100% oncology practice having seen over 10,000 patients over the past 18 years with a team of associates, management, assistants, nurses and medical lab assistants.
In 2012 we brought in a whole body hyperthermia (WBHT) device to provide outpatient fever-range WBHT targeting between 38.5 - 40.5 degrees Celsius.
IHC Cancer Care | 2018
www.integratedhealthclinic.com

PURPOSE
To describe baseline characteristics on the use of hyperthermia as part of an integrative naturopathic treatment protocol at IHC, from June 2010 -> July 2018.
To assess the safety profile for fever-range WBHT and LRHT.
To assess 5 year survival patterns for IHC's top ten treated cancer types including glioblastoma multiforme (GBM), stage 4 colorectal cancer, and non-resectable pancreatic adenocarcinoma.
METHOD
A retrospective study was conducted on all 785 patients who received hyperthermia at IHC from June 2010 to July 2018.
Patient Inclusion criteria:
Only distant metastatic disease (stage IV) for all 10 cancer types.
Received a minimum of 6 LRHT treatments.
Evaluation measures included:
Baseline Measures: date of diagnosis, stage at diagnosis, stage at new patient visit, concurrent treatments, and previously tried therapies.
Overall survival was assessed over 5 years using Kaplan-Meier plots.

RESULTS

- As of July 2018, the IHC has treated **1289** and **327** patients using LRHT and WBHT respectively.
- **785** of these patients met all the criteria to be included in our dataset.
- **16,752 LRHT** and **1082 WBHT** treatments have been administered between June 2010 & June 2018.
- 66% of patients had metastatic cancers at their initial IHC visit, compared to 49% at initial diagnosis.

Global Cancer Group Population Frequency Data.

For top **All** Cancer Groups at IHC (for 785 patients)



IHC Cancer Care | 2018

www.integratedhealthclinic.com

Cancer Group & Frequency Data.

For top **10** Cancer Groups
(for 737 patients)

Cancer_Group	Frequency	Percent
Digestive System	228	29.08
Breast	136	17.35
Respiratory System	80	10.2
Female Genital System	74	9.44
Male Genital System	64	8.16
Brain & Nervous System	54	6.89
Urinary System	36	4.59
Oral Cavity & Pharynx	28	3.57
Skin	19	2.42
Soft Tissue	18	2.3

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Global Cancer Types Population Frequency Data.

For top **All** Cancer Groups at IHC
(for 785 patients)



IHC Cancer Care | 2018 www.integratedhealthclinic.com

Cancer Type & Frequency Data.

For top **10** Cancer Types
(for 579 patients)

Cancer_Type	Frequency	Percent
Breast	135	29.08
Colon	94	17.35
Lung & Bronchus	78	10.2
Prostate	61	9.44
Brain	54	8.16
Ovary	43	6.89
Pancreas	40	4.59
Rectum	48	3.57
Kidney & Renal Pelvis	19	2.42
Soft Tissue	17	2.3

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Cancer Type & Frequency Data.

For top **10** Cancer Types
(for 579 patients)



IHC Cancer Care | 2018 www.integratedhealthclinic.com

For top **7** Cancer Types

Kaplan-Meier by Cancer Type

Colon – Stage IV



IHC Cancer Care | 2018 www.integratedhealthclinic.com

For top **7** Cancer Types

Kaplan-Meier by Cancer Type

Breast – Stage IV



IHC Cancer Care | 2018 www.integratedhealthclinic.com

For top **7** Cancer Types

Kaplan-Meier by Cancer Type

Lung – Stage IV



For top **7** Cancer Types

Kaplan-Meier by Cancer Type

Brain (GBM) – Stage IV



For top **7** Cancer Types

Kaplan-Meier by Cancer Type

Pancreas – Stage IV



IHC Cancer Care | 2018 www.integratedhealthclinic.com

For top **7** Cancer Types

Kaplan-Meier by Cancer Type

Ovary– Stage IV



IHC Cancer Care | 2018 www.integratedhealthclinic.com

For top **7** Cancer Types

Kaplan-Meier by Cancer Type

Prostate – Stage IV



Adverse Effects.

LRHT – Superficial Skin Blisters - **7**
LRHT - Subcutaneous Fibrosis - **5**

FR-WBHT - Superficial Skin Blisters - **3**
FR-WBHT – Urethral Catheter Bleed - **1**

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Conclusions.

- Preliminary results show **promising survival trajectories** for all ten most commonly treated cancer types we have reviewed in this retrospective data analysis
- Hyperthermia proves to be **a safe adjunctive treatment** in integrative oncology care.
- Further research is necessary to assess the effectiveness of hyperthermia using a larger sample population and over a longer period of time.

Future Plans.

- A **prospective study** is now underway at the IHC to further assess the impact of our naturopathic integrative protocols on OS.
- A '**best case series'** will be published to disseminate knowledge on the use of our protocols as an adjunct treatment.
- We are one of **7 clinics in North America** chosen to participate in the CUSIOS Trial to assess the benefits of advanced integrative naturopathic oncology with standard of care in several stage 3-4 cancers

Acknowledgements.

Kathy Li, PhD
• Statistician

Erin Rurak, BSc, ND
• Synthesis

Mark Elderfield, MSc
• Co-ordinator

Sarah Soles, ND
• Data

Emma Lee, BSc
• Data

References

1. Viglianti BL, Stauffer P, Repasky E, et al. Chapter 42: Hyperthermia, Section 10: Radiation Oncology, Cancer Medicine 8. 528-540.
2. Fiorentini G, Szasz A. Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther. 2006 Apr-Jun;2(2):41-6. Review.
3. De Haas-Kock DF, Buijsen J, Pijls-Johannesma M, et al. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev. 2009 Jul;8;(3):CD006269. Doi:10.1002/14651858.
4. Lutgens L, van der Zee J, et al. Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma. Cochrane Database Syst. Rev. 2010 Mar 17;(3):CD006377.doi:10.1002/14651858.CD006377.
5. Issels RD, Lindner LH, Verweijj J, et al. Effect of Neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue saracoma. Jama Oncology. 2018. Doi:10.1001/jamaoncol.2017.4996.
6. Falk MH, Issels RD. Hyperthermia in Oncology. Int J Hyperthermia. 2001 Jan-Feb;17(1):1-18.
7. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56.
8. Csoboz B, Balogh GE, Kusz E, et al. Membrane fluidity matters: hyperthermia from the aspects of lipids and membranes. Int J Hyperthermia. 2013 Aug;29(5):491-9. doi: 10.3109/02656736.2013.808765.
9. Bull JM, Strebel FR, Jenkins GN, et al. The importance of schedule in whole body thermochemotherapy. Int J Hyperthermia. 2008 Mar;24(2):171-181.
10. Roussakow V.S. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. BMJ Open. 2017; 7:e017387. Doi:10.1136/bmjopen-2017-017387.

IHC Cancer Care | 2018 www.integratedhealthclinic.com

References

11. Horseman MR, Overgaard J. Hyperthermia: A potent enhancer of radiotherapy. Clinical Oncology. 2007 19:418-426.
12. Huilgol NG, Gupta S, Sridhar CR. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: A report of a randomized trial. Journal of Cancer Research and Therapeutics. 2010:6(4):492-496.
13. Valdagni 1994
14. Frey B, Weiss EM, Rubner Y, et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia. 2012. 28(6):528-542.
15. Bull JMC. A reviwew of immune therapy in cancer and a question: can thermal therapy increase tumor response?. Int J Hyperthermia. 2018 Sep;34(6):840-852.
16. Gadaleta-Calderola G, Infusino S, Galise I, et al. Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study. 2014. Oncology Letters 8:1783-1787.
17. Ou J, Zhu X, Lu Y, et al. The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer. European Journal of Pharmaceutical Sciences. 2017. 109:412-418. http://dx.doi.org/10.1016/j.ejps.2017.08.011.
18. Curley SA, Palalon F, Sanders KE, et al. The Effects of Non-Invasive Radiofrequency Treatment and Hyperthermia on Malignant and Nonmalignant Cells. Int. J. Environ. Res. Public Health. 2014, 11, 9142-9153. doi:10.3390/ijerph110909142.
19. Pang C, Zhang X, Wang Z, et al. Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for the treatment of peritoneal carcinomatosis with malignant ascites: A phase II randomized trial. Molecular and Clinical Oncology. 2017; 6:723-732. DOI: 10.3892/mco.2017.1221

References

20. Bonucci M, Pastore C, Ferrara V, et al. Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases. Integrative Cancer Therapies. 2018:1-6. DOI: 10.1177/1534735418755479.
21. Overgaard J. (1989) The current and potential role of hyperthermia in radio-therapy International Journal of Radiation, Oncology, Biology and Physics Vol. 16, No. 3, pp: 535-549
22. Hehr T., Wust P., Bamberg M., Budach W. (2003) Current and potential role of thermoradiotherapy for solid tumours Onkologie Vol. 26, No. 3, pp: 295-302
23. Horsman, M. R., Overgaard J. (2007) Hyperthermia: a Potent Enhancer of Radiotherapy Clinical Oncology Vol. 19, pp: 418-426
24. Song C.W., Shakil A., Griffin R.J., Okajima K. (1997) Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen Seminars in Oncology Vol. 24, No. 6, pp: 626-632
25. Griffin R.J., Ogawa A., Williams B.W., Song C.W. (2005) Hyperthermic Enhancement of Tumor Radiosensitization Strategies Immunological Investigations Vol. 34, No. 3, pp: 343-359
26. Pandita T.K., Pandita S., Bhaumik S.R. (2009) Molecular parameters of hyperthermia for radiosensitization Critical Reviews in Eukaryotic Gene Expression Vol. 19, No. 3, pp: 235-251

IHC Cancer Care | 2018 www.integratedhealthclinic.com

Integrated Health Clinic
Cancer Care Center
THANK YOU
Fort Langley BC Canada